Protocol Ledger

NCT05664750 · Phase III · COMPLETED

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

Interventional Phase III clinical trial protocol NCT05664750 sponsored by Zhuhai Trinomab Pharmaceutical Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-22 Enrollment: 675 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05664750
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)675 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05664750
Protocol FieldVerified Registry Value
NCT IdentifierNCT05664750
Consolidated Lead SponsorZhuhai Trinomab Pharmaceutical Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment675 participants (ACTUAL)
Registered Start Date2022-12-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI